K
Korea Pharma Co Ltd
KOSDAQ:032300
Korea Pharma Co Ltd
KOSDAQ:032300
Price:
13 660
KRW
3.88%
Market Closed
Market Cap:
₩149B
Balance Sheet
Balance Sheet Decomposition
Korea Pharma Co Ltd
Korea Pharma Co Ltd
Balance Sheet Decomposition is not available for
Korea Pharma Co Ltd
Korea Pharma Co Ltd
Balance Sheet
Korea Pharma Co Ltd
Korea Pharma Co Ltd
Currency: KRW
| Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Cash Equivalents |
7 197
|
10 443
|
16 865
|
56 540
|
8 390
|
41 424
|
7 986
|
|
| Cash |
17
|
4
|
0
|
0
|
0
|
15 000
|
0
|
|
| Cash Equivalents |
7 180
|
10 439
|
16 865
|
56 540
|
8 390
|
26 424
|
7 986
|
|
| Short-Term Investments |
360
|
0
|
2 000
|
6 000
|
55 686
|
10 529
|
30 739
|
|
| Total Receivables |
19 014
|
16 693
|
16 110
|
17 598
|
16 419
|
14 624
|
15 542
|
|
| Accounts Receivables |
17 802
|
15 026
|
15 458
|
16 765
|
15 371
|
14 121
|
15 031
|
|
| Other Receivables |
1 212
|
1 667
|
652
|
833
|
1 049
|
503
|
511
|
|
| Inventory |
10 464
|
12 913
|
19 524
|
16 910
|
17 292
|
18 546
|
18 906
|
|
| Other Current Assets |
1 985
|
333
|
316
|
187
|
296
|
262
|
461
|
|
| Total Current Assets |
39 020
|
40 382
|
54 815
|
97 236
|
98 083
|
85 385
|
73 634
|
|
| PP&E Net |
17 091
|
18 259
|
18 824
|
20 149
|
22 130
|
23 534
|
24 010
|
|
| PP&E Gross |
17 091
|
18 259
|
18 824
|
20 149
|
22 130
|
23 534
|
24 010
|
|
| Accumulated Depreciation |
11 847
|
13 057
|
14 928
|
16 693
|
17 914
|
19 893
|
21 704
|
|
| Intangible Assets |
11
|
2 084
|
2 467
|
2 973
|
2 865
|
4 405
|
4 921
|
|
| Long-Term Investments |
4 158
|
3 869
|
3 965
|
7 924
|
6 913
|
7 515
|
9 330
|
|
| Other Long-Term Assets |
1 950
|
2 153
|
1 249
|
1 120
|
956
|
464
|
492
|
|
| Total Assets |
62 231
N/A
|
66 747
+7%
|
81 320
+22%
|
129 401
+59%
|
130 947
+1%
|
121 303
-7%
|
112 387
-7%
|
|
| Liabilities | ||||||||
| Accounts Payable |
6 199
|
8 344
|
8 690
|
6 721
|
7 098
|
7 284
|
7 400
|
|
| Accrued Liabilities |
693
|
767
|
787
|
857
|
863
|
699
|
910
|
|
| Short-Term Debt |
11 549
|
9 771
|
10 000
|
7 000
|
4 000
|
5 160
|
4 000
|
|
| Current Portion of Long-Term Debt |
760
|
6 144
|
3 900
|
3 489
|
49 902
|
13 581
|
256
|
|
| Other Current Liabilities |
9 459
|
8 652
|
7 276
|
7 431
|
7 672
|
6 576
|
6 756
|
|
| Total Current Liabilities |
28 660
|
33 678
|
30 654
|
25 498
|
69 535
|
33 300
|
19 321
|
|
| Long-Term Debt |
6 510
|
1 144
|
52
|
43 238
|
727
|
16 123
|
18 646
|
|
| Deferred Income Tax |
0
|
0
|
0
|
0
|
0
|
1 322
|
581
|
|
| Other Liabilities |
4 819
|
5 328
|
4 112
|
3 198
|
869
|
1 977
|
2 397
|
|
| Total Liabilities |
39 989
N/A
|
40 149
+0%
|
34 818
-13%
|
71 934
+107%
|
71 132
-1%
|
52 722
-26%
|
40 946
-22%
|
|
| Equity | ||||||||
| Common Stock |
4 393
|
4 393
|
5 453
|
5 453
|
5 453
|
5 453
|
5 453
|
|
| Retained Earnings |
13 224
|
16 922
|
20 056
|
26 019
|
21 750
|
19 694
|
22 411
|
|
| Additional Paid In Capital |
692
|
692
|
17 556
|
23 407
|
31 175
|
39 169
|
39 169
|
|
| Unrealized Security Profit/Loss |
4 407
|
4 407
|
4 407
|
3 437
|
3 481
|
6 202
|
6 200
|
|
| Other Equity |
474
|
185
|
969
|
850
|
2 045
|
1 937
|
1 792
|
|
| Total Equity |
22 241
N/A
|
26 598
+20%
|
46 502
+75%
|
57 467
+24%
|
59 815
+4%
|
68 582
+15%
|
71 441
+4%
|
|
| Total Liabilities & Equity |
62 231
N/A
|
66 747
+7%
|
81 320
+22%
|
129 401
+59%
|
130 947
+1%
|
121 303
-7%
|
112 387
-7%
|
|
| Shares Outstanding | ||||||||
| Common Shares Outstanding |
9
|
9
|
11
|
11
|
11
|
11
|
11
|
|
Switch to:
Switch to:
See Also
Discover More
